Japan Hospice Holdings Inc
Japan Hospice Holdings Inc provides hospice and palliative care services in Japan, generating revenue primarily through patient care and related healthcare services.
Business. Japan Hospice Holdings Inc (7061.T) is a healthcare services company primarily engaged in the operation of hospice and palliative care facilities. The firm is headquartered in Japan and is listed on the Tokyo Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Japan Hospice Holdings Inc (7061.T) is a healthcare services company primarily engaged in the operation of hospice and palliative care facilities. The firm is headquartered in Japan and is listed on the Tokyo Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Japan Hospice Holdings Inc has a market price of 639 JPY per share, with a market capitalization of 5,399,939,790 JPY. The company's price-to-earnings ratio is 35.52, and its price-to-book ratio is 1.85, indicating a moderate premium over book value. The enterprise value to EBITDA ratio is 54.81, suggesting a high valuation relative to earnings before interest, taxes, depreciation, and amortization. The company's liquidity position is characterized by a current ratio of 1.93, which is above 1, indicating that it can cover its short-term liabilities with its short-term assets.
In terms of profitability, the company's return on equity is 5.2%, and its return on assets is 1.01%, both of which are below the industry median for Healthcare Facilities & Services. The company's operating income margin is 9.83%, and its net income margin is 5.58%, which are also below the industry median. The company's debt-to-equity ratio is 3.69, indicating a high level of leverage, which is a concern given the industry's preference for lower debt levels.
The company's revenue is concentrated in Japan, with no disclosed geographic diversification. The company operates in a single business segment, which is hospice and palliative care services. This lack of diversification increases the company's exposure to local market conditions and regulatory changes.
Looking at the company's growth trajectory, the current fiscal year is expected to see a revenue increase of 11.5% compared to the previous year. The next fiscal year is projected to see a revenue increase of 10.2%. Analysts have estimated a mean EPS of 39.20 JPY for the current fiscal year, compared to the last actual EPS of 33.08 JPY. The company's revenue is expected to grow from 14,168,930,000 JPY to 15,800,000,000 JPY in the current fiscal year.
The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag is that the company's net cash is negative after subtracting total debt, which is a concern for liquidity. The company's debt-to-equity ratio of 3.69 is high, and the company has a significant amount of long-term debt, which could impact its financial flexibility. The company's dilution risk is low, as there is no indication of significant dilution potential in the near term.
Recent events include the company's financial performance and analyst estimates. The company's last actual revenue was 14,168,930,000 JPY, and the mean revenue estimate for the current fiscal year is 15,800,000,000 JPY. The company's last actual EPS was 33.08 JPY, and the mean EPS estimate for the current fiscal year is 39.20 JPY. These figures indicate that the company is expected to outperform its previous performance in terms of both revenue and earnings per share.
- Japan Hospice Holdings Inc has a high debt-to-equity ratio of 3.69, indicating a high level of leverage.
- The company's return on equity is 5.2%, and its return on assets is 1.01%, both of which are below the industry median.
- The company's revenue is concentrated in Japan, with no disclosed geographic diversification.
- The company is expected to see a revenue increase of 11.5% in the current fiscal year and 10.2% in the next fiscal year.
- The company's liquidity position is characterized by a current ratio of 1.93, which is above 1, indicating that it can cover its short-term liabilities with its short-term assets.
Bull / Bear case
Generated · model-assistedRevenue grew at a 23.9% CAGR over four years, demonstrating strong top-line expansion momentum.
Return on equity of 5.2% surpasses the 4.6% median, showing better capital efficiency than peers.
Free cash flow improved by 13.3% year-over-year, suggesting a recovery in cash generation capabilities.
Debt-to-equity ratio of 3.69 sits in the bottom quartile, indicating excessive leverage compared to peers.
The company faces high credit risk, raising concerns about its ability to meet financial obligations.
Free cash flow turned negative at -1.68 billion JPY, highlighting ongoing cash burn issues.
In focus — financials by report
Revenue ¥3.81B, +17,5% YoY; Operating income −56,7% YoY.
- ▍Revenue ¥3.81B, +17,5% YoY
- ▍Operating income −56,7% YoY
- ▍Net income −113,0% YoY
- ▍Net margin -0.7%
Revenue ¥3.67B, +14,9% YoY; Operating income −8,1% YoY.
- ▍Revenue ¥3.67B, +14,9% YoY
- ▍Operating income −8,1% YoY
- ▍Net income −11,2% YoY
- ▍Net margin 5.1%
Revenue ¥3.46B, +16,9% YoY; Operating income −4,1% YoY.
- ▍Revenue ¥3.46B, +16,9% YoY
- ▍Operating income −4,1% YoY
- ▍Net income −16,9% YoY
- ▍Net margin 1.8%
Revenue ¥3.24B, +18,7% YoY; Operating income −72,5% YoY.
- ▍Revenue ¥3.24B, +18,7% YoY
- ▍Operating income −72,5% YoY
- ▍Net income −63,8% YoY
- ▍Net margin 1.7%
Revenue ¥3.24B; Operating income ¥342.4M.
- ▍Revenue ¥3.24B
- ▍Operating income ¥342.4M
- ▍Net margin 6.2%
Revenue ¥3.19B; Operating income ¥446.5M.
- ▍Revenue ¥3.19B
- ▍Operating income ¥446.5M
- ▍Net margin 6.7%
Revenue ¥2.96B; Operating income ¥229.9M.
- ▍Revenue ¥2.96B
- ▍Operating income ¥229.9M
- ▍Net margin 2.5%
Revenue ¥2.73B; Operating income ¥268.0M.
- ▍Revenue ¥2.73B
- ▍Operating income ¥268.0M
- ▍Net margin 5.6%
Revenue ¥14.17B, +16,9% YoY; Operating income −33,7% YoY.
- ▍Revenue ¥14.17B, +16,9% YoY
- ▍Operating income −33,7% YoY
- ▍Net income −56,5% YoY
- ▍Free cash flow +13,3% YoY
- ▍Net margin 2.0%
Revenue ¥12.12B, +22,7% YoY; Operating income +0,2% YoY.
- ▍Revenue ¥12.12B, +22,7% YoY
- ▍Operating income +0,2% YoY
- ▍Net income −6,2% YoY
- ▍Free cash flow −114,2% YoY
- ▍Net margin 5.3%
Revenue ¥9.87B, +25,1% YoY; Operating income +33,6% YoY.
- ▍Revenue ¥9.87B, +25,1% YoY
- ▍Operating income +33,6% YoY
- ▍Net income +50,0% YoY
- ▍Free cash flow −419,4% YoY
- ▍Net margin 6.9%
Revenue ¥7.89B, +31,1% YoY; Operating income +60,6% YoY.
- ▍Revenue ¥7.89B, +31,1% YoY
- ▍Operating income +60,6% YoY
- ▍Net income +88,8% YoY
- ▍Free cash flow +119,6% YoY
- ▍Net margin 5.8%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 39,20 |
| Revenue | —no estimate | —no estimate | 15,8B JPY |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Japan Hospice Holdings Inc Market data — financials · 2026-05-27
- Japan Hospice Holdings Inc Market data — analyst estimates · 2026-05-27